# KEYNOTE-057 (NCT02625961)

> Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02625961
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab; Pembrolizumab/vibostolimab coformulation; Favezelimab/pembrolizumab coformulation
- Enrollment: 296
- Primary outcome: Cohort A: Complete Response (CR) Rate of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
- Primary outcome: Cohort B: 12-month Disease-Free Survival (DFS) Rate of High-Risk NMIBC
- Primary outcome: Cohort A and B: Number of Participants Who Experience an Adverse Event (AE)
- Primary outcome: Cohort A and B: Number of Participants Who Discontinue Study Treatment Due to an AE

## Indexed commentary on KEYNOTE-057 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 40
- YouTube: 33
- Podcasts: 31
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-057-nct02625961

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02625961", "email": "<work email>"}; the inbox owner confirms by the emailed link.